Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy

Motoko Yamaguchi, Katsuyoshi Takata, Tadashi Yoshino, Naoki Ishizuka, Masahiko Oguchi, Yukio Kobayashi, Yasushi Isobe, Kenichi Ishizawa, Nobuko Kubota, Kuniaki Itoh, Noriko Usui, Kana Miyazaki, Izumi Wasada, Shigeo Nakamura, Yoshihiro Matsuno, Kazuo Oshimi, Tomohiro Kinoshita, Kunihiro Tsukasaki, Kensei Tobinai

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)


    Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66% (19/29) and 29% (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61-94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95% confidence interval [CI], 0.057-1.013; 80% CI, 0.093-0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84%) cases were of NK-cell origin, two were of αβ T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy.

    Original languageEnglish
    Pages (from-to)1435-1441
    Number of pages7
    JournalCancer science
    Issue number11
    Publication statusPublished - 2014 Nov 1


    • Clinical trial
    • Epstein-Barr virus
    • Extranodal NK/T-cell lymphoma
    • Latent membrane protein 1
    • Radiotherapy

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy'. Together they form a unique fingerprint.

    Cite this